Celcuity Inc. Reports Q1 2025 Financial Results

Celcuity Inc. ( (CELC) ) has released its Q1 earnings. Here is a breakdown of the information Celcuity Inc. presented to its investors.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, with its lead candidate gedatolisib aimed at treating multiple solid tumor indications.

In its first quarter 2025 financial report, Celcuity Inc. highlighted significant progress in its clinical trials, including the VIKTORIA-1 and VIKTORIA-2 Phase 3 trials, and announced a new collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital. The company reported a net loss of $37 million for the quarter, reflecting increased research and development expenses.

Key financial metrics revealed that Celcuity’s operating expenses rose to $36.1 million, primarily due to increased R&D activities. The company reported a net cash usage of $35.9 million in operating activities, with cash, cash equivalents, and investments totaling approximately $206 million, expected to support its clinical programs through 2026.

Strategic developments include ongoing patient enrollment for the VIKTORIA-1 trial and the initiation of the VIKTORIA-2 trial. Additionally, the company is preparing to report topline data from its CELC-G-201 study in the second quarter of 2025, which evaluates gedatolisib in combination with darolutamide for prostate cancer treatment.

Looking ahead, Celcuity remains focused on advancing its clinical pipeline, with several data readouts anticipated later in 2025. The company aims to transition to a commercial stage, contingent upon positive trial outcomes and regulatory approvals.